Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck’s COVID-19 Therapeutic Development Path Gets A Little Harder

Pharma Shelves One Drug Program, Narrows Another

Executive Summary

After backing off of MRK-7110 for hospitalized patients the company’s focus is on the oral antiviral molnupiravir for outpatients – which would be a huge win, but the drug has yet to fully prove itself in the clinic.

You may also be interested in...



Could Start-Up Adagio’s COVID-19 Antibody Have A Fighting Chance?

The company announced a $336m series C round, six months after it raised an $80m series B, to support development of an easily administered treatment ADG20.

After J&J Vaccine Pause, Urgent Safety Questions for Sputnik And CanSino

Potentially fatal blood clots seen in AZ and J&J’s COVID-19 vaccine could be common to all adenovirus vector vaccines – but Russia and China developers are dismissing a possible link.

Coronavirus Update: J&J Vaccine On Pause Amid Reports Of Clots

The CDC and FDA recommended a pause on dosing of J&J's one-shot vaccine. Pfizer/BioNTech's vaccine showed signs of lower efficacy against the B.1.351 variant, but a prominent expert called the data "misleading." Gilead halted its Phase III study of Veklury in non-hospitalized, high-risk patients. And Rigel's Tavalisse may have a shot in the sickest COVID-19 patients despite the small size of a Phase II study.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC144194

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel